NDAORALCAPSULE
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
ORIAHNN (COPACKAGED) (elagolix and estradiol and norethisterone) by AbbVie is estradiol/norethindrone acetate (e2/neta), a combination of estrogen and progestin. Approved for heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. First approved in 2020.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORIAHNN is a copackaged oral combination of elagolix (a GnRH receptor antagonist) with estradiol and norethisterone acetate, designed to treat heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Elagolix suppresses luteinizing hormone and follicle-stimulating hormone, reducing ovarian sex hormones and menstrual bleeding, while the estradiol and progestin add-back mitigate bone loss and protect the endometrium. The product represents a novel hormonal approach to a common gynecological condition affecting millions of women globally.
Peak14.1 years to LOE
At peak lifecycle stage with strong patent protection through 2040, the brand team is likely focused on market penetration, patient awareness, and defending against competitive entries in the uterine fibroid treatment space.
Mechanism of Action
estradiol/norethindrone acetate (E2/NETA), a combination of estrogen and progestin. Elagolix is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of elagolix results in dose-dependent suppression of…
Worked on ORIAHNN (COPACKAGED) at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.